Skip to main content
SpringerLink
Log in

Behavioral and Psychiatric Symptoms in Dementia (BPSD)

  • Chapter
  • First Online:
Geriatric Practice

  • 2765 Accesses

Abstract

Behavioral and psychiatric symptoms in dementia (BPSD) are common and will affect the majority of patients with dementia at some point during the course of their disease. Symptoms are fluctuating, unpredictable, and wide ranging and can change frequently in a particular patient. BPSD are costly to patients and society, can be taxing for caregivers, and are a major cause of placement in facilities. This chapter reviews the subtypes of dementia and the variety of behavioral and psychiatric symptoms commonly occurring at various stages of dementia. We present nonpharmacologic and pharmacologic approaches, utilizing a multidisciplinary team to manage these patients. The ultimate goal of treatment being improving patient care and comfort, relieve caregiver stress, and avoid institutionalization.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res [Internet]. 1975 [cited 2018 Feb 3];12(3):189–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1202204.

  2. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc [Internet]. 2005 [cited 2018 Feb 3];53(4):695–9. Available from: http://doi.wiley.com/10.1111/j.1532-5415.2005.53221.x.

  3. Spira AP, Gottesman RF. Sleep disturbance: an emerging opportunity for Alzheimer’s disease prevention? Int Psychogeriatr [Internet]. 2017 [cited 2017 Nov 26];29(4):529–31. Available from: https://www.cambridge.org/core/product/identifier/S1041610216002131/type/journal_article.

  4. Pavlova M. Circadian rhythm sleep-wake disorders. Contin Lifelong Learn Neurol [Internet]. 2017 [cited 2017 Nov 26];23(4, Sleep Neurology):1051–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28777176.

  5. Bassetti CL, Bargiotas P. REM sleep behavior disorder. Front Neurol Neurosci [Internet]. 2018 [cited 2017 Nov 26];41:104–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29145189.

  6. Kinnunen KM, Vikhanova A, Livingston G. The management of sleep disorders in dementia. Curr Opin Psychiatry [Internet]. 2017 [cited 2017 Nov 26];30(6):491–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28858007.

  7. McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev [Internet]. 2016 [cited 2018 Feb 3];11:CD009178. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27851868.

  8. Pinkhasov A, James SA, Fazzari M, Singh D, Lam S. Role of Ramelteon in reduction of as-needed antipsychotics in elderly patients with delirium in a general hospital setting. Clin Drug Investig [Internet]. 2017 [cited 2017 Dec 9];37(12):1137–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28933013.

  9. Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc [Internet]. 2016 [cited 2017 Dec 9];91(11):1632–9. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0025619616305092.

  10. Lanctôt KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, et al. Neuropsychiatric signs and symptoms of Alzheimer’s disease: new treatment paradigms. Alzheimer’s Dement Transl Res Clin Interv [Internet]. 2017 [cited 2017 Dec 9];3(3):440–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29067350.

  11. Theleritis C, Siarkos K, Katirtzoglou E, Politis A. Pharmacological and nonpharmacological treatment for apathy in Alzheimer disease. J Geriatr Psychiatry Neurol [Internet]. 2017 [cited 2017 Dec 9];30(1):26–49. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28248559.

  12. Kai K, Hashimoto M, Amano K, Tanaka H, Fukuhara R, Ikeda M. Relationship between eating disturbance and dementia severity in patients with Alzheimer’s disease. Ginsberg SD, editor. PLoS One [Internet]. 2015 [cited 2017 Nov 26];10(8):e0133666. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26266531.

  13. Abdelhamid A, Bunn D, Copley M, Cowap V, Dickinson A, Gray L, et al. Effectiveness of interventions to directly support food and drink intake in people with dementia: systematic review and meta-analysis. BMC Geriatr [Internet]. 2016 [cited 2017 Nov 26];16(1):26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26801619.

  14. Ikeda M, Brown J, Holland AJ, Fukuhara R, Hodges JR. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer’s disease. J Neurol Neurosurg Psychiatry [Internet]. 2002 [cited 2017 Nov 26];73(4):371–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12235302.

  15. Nestor PJ. Reversal of abnormal eating and drinking behaviour in a frontotemporal lobar degeneration patient using low-dose topiramate: Table 1. J Neurol Neurosurg Psychiatry [Internet]. 2012 [cited 2017 Nov 26];83(3):349–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21507895.

  16. Lanska DJ. The Klüver-Bucy syndrome. Front Neurol Neurosci [Internet]. 2018 [cited 2017 Nov 26];41:77–89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29145186.

  17. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA [Internet]. 2012 [cited 2018 Jan 13];308(19):2020. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23168825.

  18. Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease. JAMA [Internet]. 2014 [cited 2017 Nov 26];311(7):682. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24549548.

  19. Rabins P, Rover B, Rummans T, Schneider L, Trait P. Guideline watch (October 2014): practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Focus (Madison). 2017;15(1):110–28.

    Article  Google Scholar 

  20. Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry [Internet]. 2016 [cited 2017 Nov 26];173(5):543–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27133416.

  21. Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry [Internet]. 2008 [cited 2017 Nov 26];165(7):844–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18519523.

  22. Food and Drug Administration. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. [Internet]. [cited 2017 Jan 1]. Available from: https://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171.

  23. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med [Internet]. 2005 [cited 2017 Nov 26];353(22):2335–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16319382.

  24. Nielsen RE, Lolk A, Valentin JB, Andersen K. Cumulative dosages of antipsychotic drugs are associated with increased mortality rate in patients with Alzheimer’s dementia. Acta Psychiatr Scand [Internet]. 2016 [cited 2017 Nov 26];134(4):314–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27357602.

  25. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol [Internet]. 2009 [cited 2017 Nov 26];8(2):151–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19138567.

  26. Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry [Internet]. 2012 [cited 2017 Nov 26];169(1):71–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22193526.

  27. Wolf A, Leucht S, Pajonk F-G. Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials. Eur Arch Psychiatry Clin Neurosci [Internet]. 2017 [cited 2017 Dec 9];267(3):187–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27530185.

  28. Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag [Internet]. 2017 [cited 2017 Dec 9];13:757–77. Available from: https://www.dovepress.com/safety-tolerability-and-risks-associated-with-first%2D%2Dand-second-genera-peer-reviewed-article-TCRM.

  29. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology [Internet]. 1994 [cited 2017 Dec 9];44(12):2308–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7991117.

  30. Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, et al. Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med [Internet]. 2012 [cited 2017 Nov 26];367(16):1497–507. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23075176.

  31. Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. In: Declercq T, editor. Cochrane database of systematic reviews [Internet]. Chichester: Wiley; 2013 [cited 2017 Nov 26]. p. CD007726. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23543555

  32. Sahli ZT, Tarazi FI. Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis. Expert Opin Drug Discov [Internet]. 2018[cited 2018 Feb 3];13(1):103–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29047301.

  33. Maust DT, Bonar EE, Ilgen MA, Blow FC, Kales HC. Agitation in Alzheimer disease as a qualifying condition for medical marijuana in the United States. Am J Geriatr Psychiatry [Internet]. 2016 [cited 2018 Jan 13];24(11):1000–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27389672.

  34. van den Elsen GAH, Ahmed AIA, Verkes R-J, Kramers C, Feuth T, Rosenberg PB, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial. Neurology [Internet]. 2015 [cited 2018 Jan 13];84(23):2338–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25972490.

  35. van den Elsen GAH, Ahmed AIA, Verkes R-J, Feuth T, van der Marck MA, Olde Rikkert MGM. Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial. Am J Geriatr Psychiatry [Internet]. 2015 Dec [cited 2018 Jan 13];23(12):1214–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26560511.

  36. De Asis J, Stern E, Alexopoulos GS, Pan H, et al. Hippocampal and anterior cingulate activation deficits in patients with geriatric depression. Am J Psychiatry. 2001;158:1321–3.

    Article  Google Scholar 

  37. Borisovskaya A, Augsburger J, Pascualy M. Electroconvulsive therapy for frontotemporal dementia with comorbid major depressive disorder. J ECT [Internet]. 2014 [cited 2018 Feb 3];30(4):45–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24901427.

  38. Miller A, Pratt H, Schiffer RB. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. Expert Rev Neurother [Internet]. 2011 [cited 2017 Nov 26];11(7):1077–88. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21539437.

  39. Carota A, Bogousslavsky J. Catastrophe reaction and emotionalism. Front Neurol Neurosci [Internet]. 2018 [cited 2017 Nov 26];41:50–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29145183.

  40. Sami M, Khan H, Nilforooshan R. Late onset mania as an organic syndrome: A review of case reports in the literature. J Affect Disord [Internet]. 2015 [cited 2017 Nov 26];188:226–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26368947.

  41. Ducharme S, Bajestan S, Dickerson BC, Voon V. Psychiatric presentations of C9orf72 mutation: what are the diagnostic implications for clinicians? J Neuropsychiatry Clin Neurosci [Internet]. 2017 [cited 2017 Nov 26];29(3):195–205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28238272.

  42. Samus QM, Johnston D, Black BS, Hess E, Lyman C, Vavilikolanu A, et al. A multidimensional home-based care coordination intervention for elders with memory disorders: the maximizing independence at home (MIND) pilot randomized trial. Am J Geriatr Psychiatry [Internet]. 2014 [cited 2017 Nov 26];22(4):398–414. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24502822.

  43. Dickerson BC. Dysfunction of social cognition and behavior. Continuum. American Academy of Neurology. 2015;21:660–77.

    Google Scholar 

  44. Goldstein M. Dysphasias, dyspraxias and dysexecutive syndromes: the non-memory cognitive impairments. In: Sealfon SC, Stacy CB, Motiwala R, editors. Mount Sinai expert guidelines: neurology. Malden: Wiley-Blackwell; 2016.

    Google Scholar 

  45. Aloysi A, Aron E. A 74-year old woman with anxiety and paranoid delusions. Psychiatr Ann. 2012;42(12):471–5.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Psychiatry and Neurology, Mount Sinai Hospital, New York, NY, USA

    Amy S. Aloysi

  2. Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Eileen H. Callahan

Authors
  1. Amy S. Aloysi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eileen H. Callahan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy S. Aloysi .

Editor information

Editors and Affiliations

  1. Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Audrey Chun

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Aloysi, A.S., Callahan, E.H. (2020). Behavioral and Psychiatric Symptoms in Dementia (BPSD). In: Chun, A. (eds) Geriatric Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-19625-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-19625-7_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-19624-0

  • Online ISBN: 978-3-030-19625-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation